Search

Your search keyword '"Antonino Grassadonia"' showing total 110 results

Search Constraints

Start Over You searched for: Author "Antonino Grassadonia" Remove constraint Author: "Antonino Grassadonia"
110 results on '"Antonino Grassadonia"'

Search Results

51. Neoadjuvant chemotherapy in triple-negative breast cancer: A multicentric retrospective observational study in real-life setting

52. Long-term outcome of breast cancer patients with pathologic N3a lymph node stage

53. The Benzimidazole-Based Anthelmintic Parbendazole: A Repurposed Drug Candidate That Synergizes with Gemcitabine in Pancreatic Cancer

54. Circulating Cancer Stem Cell-Derived Extracellular Vesicles as a Novel Biomarker for Clinical Outcome Evaluation

55. Prognostic relevance of DNA damage and repair biomarkers in elderly patients with hormone-receptor-positive breast cancer treated with neoadjuvant hormone therapy: evidence from the real-world setting

56. Palbociclib plus endocrine therapy in HER2 negative, hormonal receptor-positive, advanced breast cancer: A real-world experience

57. Palliative radiotherapy in advanced cancer patients treated with immune‑checkpoint inhibitors: The PRACTICE study

58. Correlations Between the Immune-related Adverse Events Spectrum and Efficacy of Anti-PD1 Immunotherapy in NSCLC Patients

59. Impact of primary tumor location in patients with RAS wild-type metastatic colon cancer treated with first-line chemotherapy plus anti-EGFR or anti-VEGF monoclonal antibodies: A retrospective multicenter study

60. Clinical Outcomes of Patients with Advanced Cancer and Pre-Existing Autoimmune Diseases Treated with Anti-Programmed Death-1 Immunotherapy: A Real-World Transverse Study

61. Exosomes as Pleiotropic Players in Pancreatic Cancer

62. A Real-World Multicentre Retrospective Study of Paclitaxel-Bevacizumab and Maintenance Therapy as First-Line for HER2-Negative Metastatic Breast Cancer

63. Neoadjuvant Immune-Checkpoint Blockade in Triple-Negative Breast Cancer: Current Evidence and Literature-Based Meta-Analysis of Randomized Trials

64. The Role of Dysfunctional Adipose Tissue in Pancreatic Cancer: A Molecular Perspective

65. Corrigendum to 'Circulating Cancer Stem Cell-Derived Extracellular Vesicles as a Novel Biomarker for Clinical Outcome Evaluation'

66. Combination of peripheral neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio is predictive of pathological complete response after neoadjuvant chemotherapy in breast cancer patients

67. Effect of Gender on the Outcome of Patients Receiving Immune Checkpoint Inhibitors for Advanced Cancer: A Systematic Review and Meta-Analysis of Phase III Randomized Clinical Trials

68. Peripheral neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio are predictive of pathological complete response after neoadjuvant chemotherapy for breast cancer

69. Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial

70. Body mass index in HER2-negative metastatic breast cancer treated with first-line paclitaxel and bevacizumab

71. Body Mass Index and Treatment Outcomes in Metastatic Breast Cancer Patients Treated With Eribulin

72. Is the skin a sanctuary for breast cancer cells during treatment with anti-HER2 antibodies?

73. Identification of Subgroups of Early Breast Cancer Patients at High Risk of Nonadherence to Adjuvant Hormone Therapy: Results of an Italian Survey

74. Effect of Targeted Agents on the Endocrine Response of Breast Cancer in the Neoadjuvant Setting: A Systematic Review

75. Reply to Kadri Altundag: Do cut-off values of lymph node ratio and presence of perineural invasion affect survival in breast cancer patients with pathologic N3a lymph node stage?

76. Inhibition of Tumor Growth and Angiogenesis by SP-2, an Anti–Lectin, Galactoside-Binding Soluble 3 Binding Protein (LGALS3BP) Antibody

77. Long-Term Outcome of Neoadjuvant Endocrine Therapy with Aromatase Inhibitors in Elderly Women with Hormone Receptor-Positive Breast Cancer

78. Effectiveness of neoadjuvant trastuzumab and chemotherapy in HER2-overexpressing breast cancer

79. Circulating Autoantibodies to LGALS3BP: A Novel Biomarker for Cancer

80. Fulvestrant 500 milligrams as endocrine therapy for endocrine sensitive advanced breast cancer patients in the real world: the Ful500 prospective observational trial

81. Body Mass Index and Treatment Outcomes in Metastatic Breast Cancer Patients Treated With Eribulin

82. Long-term outcome of neoadjuvant systemic therapy for locally advanced breast cancer in routine clinical practice

83. An Epigenetic Approach to Pancreatic Cancer Treatment: The Prospective Role of Histone Deacetylase Inhibitors

84. Upstream Stimulatory Factor Regulates Constitutive Expression and Hormonal Suppression of the 90K (Mac-2BP) Protein

85. The 90K Protein Increases Major Histocompatibility Complex Class I Expression and Is Regulated by Hormones, γ-Interferon, and Double-Strand Polynucleotides

86. Resveratrol inhibits sodium/iodide symporter gene expression and function in rat thyroid cells

87. Thyroglobulin Repression of Thyroid Transcription Factor 1 (TTF-1) Gene Expression Is Mediated by Decreased DNA Binding of Nuclear Factor I Proteins Which Control Constitutive TTF-1 Expression

88. [Untitled]

89. Relief of Symptoms After Gefitinib Is Associated With Improvement of Rest/Activity Rhythm in Advanced Lung Cancer

90. The flavonoid quercetin inhibits thyroid-restricted genes expression and thyroid function

91. Breast cancer follow-up strategies in randomized phase III adjuvant clinical trials: a systematic review

92. Role of Hydroxamate-Based Histone Deacetylase Inhibitors (Hb-HDACIs) in the Treatment of Solid Malignancies

93. Tumor-derived microvesicles: the metastasomes

94. New Targets for Therapy in Pancreatic Cancer

95. 90k is a serum marker of poor-prognosis in non-hodgkins-lymphoma patients

96. Molecular mechanisms of endocrine resistance and their implication in the therapy of breast cancer

97. A phase II study of dose-dense epirubicin plus cyclophosphamide followed by docetaxel plus capecitabine and pegfilgrastim support as preoperative therapy for patients with stage II, IIIA breast cancer

98. Impact of Body Mass Index (BMI) on outcome of metastatic breast cancer (MBC) patients (pts) treated with Eribulin in a real-world population: a multicenter retrospective study

99. Erratum to 'Chemotherapy-induced nausea and vomiting in Italian cancer centers: results of CINVDAY, a prospective, multicenter study' - Tumori. 2014 Nov-Dec;100(6):e309-13

100. Abstract 2684: Inhibition of tumor growth and angiogenesis by SP-2, an anti-LGALS3BP antibody

Catalog

Books, media, physical & digital resources